Atezolizumab Improves Survival vs Docetaxel in Previously Treated Non–Small Cell Lung Cancer


“In the phase III OAK trial reported in The Lancet by Rittmeyer et al, treatment with the anti–programmed cell death ligand 1 (PD-L1) antibody atezolizumab (Tecentriq) improved overall survival vs docetaxel in previously treated non–small cell lung cancer (NSCLC). Results of the trial supported the recent approval of atezolizumab in metastatic NSCLC in patients who have received prior platinum-containing therapy.”

Go to full article.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to use our ASK Cancer Commons service.